S&P Futures
5,899.50 +3.00 (+0.05%) Dow Futures
43,432.00 -136.00 (-0.31%) Nasdaq Futures
20,570.75 +77.00 (+0.38%) Russell 2000 Futures
2,319.70 +6.10 (+0.26%) Crude Oil
67.32 +0.30 (+0.45%) Gold
2,597.40 +27.30 (+1.06%)
Vor Biopharma Inc. (VOR)
After hours:
| Previous Close | 0.8973 |
| Open | 0.9300 |
| Bid | 0.8105 x 200 |
| Ask | 0.8958 x 100 |
| Day's Range | 0.8400 - 0.9300 |
| 52 Week Range | 0.6300 - 3.1400 |
| Volume | |
| Avg. Volume | 1,004,501 |
| Market Cap | 59.327M |
| Beta (5Y Monthly) | -0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6400 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 |
GlobeNewswireVor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update. “We are pleased with our opera
- GlobeNewswire
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company’s President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management,
